세계의 유전체 맞춤형 의료 시장 조사 보고서 : 산업 분석, 규모, 점유율, 성장, 동향, 예측(2024-2032년)

The global demand for Genomics Personalized Health Market is presumed to reach the market size of nearly USD 87.41 Billion by 2032 from USD 56.78 Billion in 2023 with a CAGR of 4.91% under the study period 2024-2032.

Genomic personalized health is a unique approach to healthcare in which a patient's medical treatment is modified based on genetic information. A more sophisticated system has evolved from a better understanding of the human genome and ways for physicians to use that information in their patients' medical and surgical management. These can aid in diagnosing a wide range of complex disorders and lead to the development of more customized treatments based on genetic profiling, removing some conventional medications that may fail or have adverse side effects in a specific patient population. The research focuses on the design, development, and use of genomic discovery, analysis, and translation methodologies to promote genomics-driven healthcare and improve clinical and personalized health outcomes. Personalized medicine is a new field that uses a person's genetic profile to help guide decisions about illness prevention, diagnosis, and treatment. Doctors can use a patient's genetic profile to assist them in choosing the proper medication or therapy for them and administer it at the correct dose or regimen.

MARKET DYNAMICS

The global genomics personalized health market is driven by rising spending on research and development activities tied to biomarkers. Demand for genomics-based personalized health is expected to increase as chronic diseases like cancer and diabetes become more prevalent. The pharmaceutical sector's expansion and the assessment and prediction of treatment response are projected to propel the industry forward. Furthermore, the personalized genomics health market is affected by the booming molecular biology sector and technological advancements in the healthcare sector. Again, the growing elderly population has increased the prevalence of several chronic diseases, boosting the market's growth. Increased investment by diagnostic health care and governments is expected to be a critical driver of the genomics personalized health market's growth. However, the market expansion is hampered by a lack of awareness in emerging nations, time-consuming regulatory rules, data security and regulatory concerns, and significant data management issues.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Genomics Personalized Health. The growth and trends of Genomics Personalized Health industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Genomics Personalized Health market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Technology

• NGS Platforms
• RT-PCR
• Microarray
• Genetic Analyzers

By Test

• Oncology Testing
• Infectious Disease Testing
• Autoimmune Disease Testing
• Others

By End-User

• Academics & Research Institutes
• Diagnostic Centers
• Others

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Genomics Personalized Health market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Genomics Personalized Health market include Illumine, QIAGEN, Thermo Fisher Scientific, Bio-Rad Laboratories, Roche, Lonza Group. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1. PREFACE

• 1.1. Report Description
  • 1.1.1 Objective
  • 1.1.2 Target Audience
  • 1.1.3 Unique Selling Proposition (USP) & offerings
• 1.2. Research Scope
• 1.3. Research Methodology
  • 1.3.1 Market Research Process
  • 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

• 2.1. Highlights of Market
• 2.2. Global Market Snapshot

3. GENOMICS PERSONALIZED HEALTH - INDUSTRY ANALYSIS

• 3.1. Introduction - Market Dynamics
• 3.2. Market Drivers
• 3.3. Market Restraints
• 3.4. Opportunities
• 3.5. Industry Trends
• 3.6. Porter's Five Force Analysis
• 3.7. Market Attractiveness Analysis
  • 3.7.1 Market Attractiveness Analysis By Technology
  • 3.7.2 Market Attractiveness Analysis By Test
  • 3.7.3 Market Attractiveness Analysis By End-User
  • 3.7.4 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

• 4.1. Value Chain Analysis
• 4.2. Raw Material Analysis
  • 4.2.1 List of Raw Materials
  • 4.2.2 Raw Material Manufactures List
  • 4.2.3 Price Trend of Key Raw Materials
• 4.3. List of Potential Buyers
• 4.4. Marketing Channel
  • 4.4.1 Direct Marketing
  • 4.4.2 Indirect Marketing
  • 4.4.3 Marketing Channel Development Trend

5. GLOBAL GENOMICS PERSONALIZED HEALTH MARKET ANALYSIS BY TECHNOLOGY

• 5.1. Overview By Technology
• 5.2. Historical and Forecast Data Analysis By Technology
• 5.3. NGS Platforms Historic and Forecast Sales By Regions
• 5.4. RT-PCR Historic and Forecast Sales By Regions
• 5.5. Microarray Historic and Forecast Sales By Regions
• 5.6. Genetic Analyzers Historic and Forecast Sales By Regions

6. GLOBAL GENOMICS PERSONALIZED HEALTH MARKET ANALYSIS BY TEST

• 6.1. Overview By Test
• 6.2. Historical and Forecast Data Analysis By Test
• 6.3. Oncology Testing Historic and Forecast Sales By Regions
• 6.4. Infectious Disease Testing Historic and Forecast Sales By Regions
• 6.5. Autoimmune Disease Testing Historic and Forecast Sales By Regions
• 6.6. Others Historic and Forecast Sales By Regions

7. GLOBAL GENOMICS PERSONALIZED HEALTH MARKET ANALYSIS BY END-USER

• 7.1. Overview By End-User
• 7.2. Historical and Forecast Data Analysis By End-User
• 7.3. Academics & Research Institutes Historic and Forecast Sales By Regions
• 7.4. Diagnostic Centers Historic and Forecast Sales By Regions
• 7.5. Others Historic and Forecast Sales By Regions

8. GLOBAL GENOMICS PERSONALIZED HEALTH MARKET ANALYSIS BY GEOGRAPHY

• 8.1. Regional Outlook
• 8.2. Introduction
• 8.3. North America Sales Analysis
  • 8.3.1 Overview, Historic and Forecast Data Sales Analysis
  • 8.3.2 North America By Segment Sales Analysis
  • 8.3.3 North America By Country Sales Analysis
  • 8.3.4 United States Sales Analysis
  • 8.3.5 Canada Sales Analysis
  • 8.3.6 Mexico Sales Analysis
• 8.4. Europe Sales Analysis
  • 8.4.1 Overview, Historic and Forecast Data Sales Analysis
  • 8.4.2 Europe By Segment Sales Analysis
  • 8.4.3 Europe By Country Sales Analysis
  • 8.4.4 United Kingdom Sales Analysis
  • 8.4.5 France Sales Analysis
  • 8.4.6 Germany Sales Analysis
  • 8.4.7 Italy Sales Analysis
  • 8.4.8 Russia Sales Analysis
  • 8.4.9 Rest Of Europe Sales Analysis
• 8.5. Asia Pacific Sales Analysis
  • 8.5.1 Overview, Historic and Forecast Data Sales Analysis
  • 8.5.2 Asia Pacific By Segment Sales Analysis
  • 8.5.3 Asia Pacific By Country Sales Analysis
  • 8.5.4 China Sales Analysis
  • 8.5.5 India Sales Analysis
  • 8.5.6 Japan Sales Analysis
  • 8.5.7 South Korea Sales Analysis
  • 8.5.8 Australia Sales Analysis
  • 8.5.9 South East Asia Sales Analysis
  • 8.5.10 Rest Of Asia Pacific Sales Analysis
• 8.6. Latin America Sales Analysis
  • 8.6.1 Overview, Historic and Forecast Data Sales Analysis
  • 8.6.2 Latin America By Segment Sales Analysis
  • 8.6.3 Latin America By Country Sales Analysis
  • 8.6.4 Brazil Sales Analysis
  • 8.6.5 Argentina Sales Analysis
  • 8.6.6 Peru Sales Analysis
  • 8.6.7 Chile Sales Analysis
  • 8.6.8 Rest of Latin America Sales Analysis
• 8.7. Middle East & Africa Sales Analysis
  • 8.7.1 Overview, Historic and Forecast Data Sales Analysis
  • 8.7.2 Middle East & Africa By Segment Sales Analysis
  • 8.7.3 Middle East & Africa By Country Sales Analysis
  • 8.7.4 Saudi Arabia Sales Analysis
  • 8.7.5 UAE Sales Analysis
  • 8.7.6 Israel Sales Analysis
  • 8.7.7 South Africa Sales Analysis
  • 8.7.8 Rest Of Middle East And Africa Sales Analysis

9. COMPETITIVE LANDSCAPE OF THE GENOMICS PERSONALIZED HEALTH COMPANIES

• 9.1. Genomics Personalized Health Market Competition
• 9.2. Partnership/Collaboration/Agreement
• 9.3. Merger And Acquisitions
• 9.4. New Product Launch
• 9.5. Other Developments

10. COMPANY PROFILES OF GENOMICS PERSONALIZED HEALTH INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Market Concentration Rate
• 10.3. Illumine
  • 10.3.1 Company Overview
  • 10.3.2 Company Revenue
  • 10.3.3 Products
  • 10.3.4 Recent Developments
• 10.4. QIAGEN
  • 10.4.1 Company Overview
  • 10.4.2 Company Revenue
  • 10.4.3 Products
  • 10.4.4 Recent Developments
• 10.5. Thermo Fisher Scientific
  • 10.5.1 Company Overview
  • 10.5.2 Company Revenue
  • 10.5.3 Products
  • 10.5.4 Recent Developments
• 10.6. Bio-Rad Laboratories
  • 10.6.1 Company Overview
  • 10.6.2 Company Revenue
  • 10.6.3 Products
  • 10.6.4 Recent Developments
• 10.7. Roche
  • 10.7.1 Company Overview
  • 10.7.2 Company Revenue
  • 10.7.3 Products
  • 10.7.4 Recent Developments
• 10.8. Lonza Group
  • 10.8.1 Company Overview
  • 10.8.2 Company Revenue
  • 10.8.3 Products
  • 10.8.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies